Literature DB >> 21056994

Mathematical and experimental approaches to identify and predict the effects of chemotherapy on neuroglial precursors.

Ollivier Hyrien1, Jörg Dietrich, Mark Noble.   

Abstract

UNLABELLED: The adverse effects of chemotherapy on normal cells of the body create substantial clinical problems for many cancer patients. However, relatively little is known about the effects, other than promotion of cell death, of such agents on the function of normal precursor cells critical in tissue homeostasis and repair. We have combined mathematical and experimental analyses to identify the effects of sublethal doses of chemotherapy on glial precursor cells of the central nervous system. We modeled the temporal development of a population of precursor and terminally differentiated cells exposed to sublethal doses of carmustine (BCNU), a classic alkylating chemotherapeutic agent used in treatment of gliomas and non-Hodgkin's lymphomas, as a multitype age-dependent branching process. We fitted our model to data from in vitro clonal experiments using the method of pseudo-likelihood. This approach identifies several novel drug effects, including modification of the cell cycle length, the time between division and differentiation, and alteration in the probability of undergoing self-renewal division in precursor cells. These changes of precursor cell function in the chemotherapy-exposed brain may have profound clinic implications. MAJOR
FINDINGS: We applied our computational approach to analyze the effects of BCNU on clonal cultures of oligodendrocyte progenitor cells-one of the best-characterized neural progenitor cells in the mammalian brain. Our analysis reveals that transient exposures to BCNU increased the cell cycle length of progenitor cells and decreased their time to differentiation, while also decreasing the likelihood that they will undergo self-renewing divisions. By investigating the behavior of our mathematical model, we demonstrate that precursor cell populations should recover spontaneously from transient modifications of the timing of division and of differentiation, but such recovery will not happen after alteration of cell fate. These studies identify means by which precursor cell function can be critically compromised by transient exposure to chemotherapy with long-term consequences on the progenitor cell pool even in the absence of drug-induced apoptosis. These analyses also provide novel tools that apply broadly to identify effects of chemotherapeutic agents and other physiological stressors. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056994      PMCID: PMC3035395          DOI: 10.1158/0008-5472.CAN-10-1400

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell.

Authors:  J Smith; E Ladi; M Mayer-Proschel; M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

2.  An alternative stochastic model of generation of oligodendrocytes in cell culture.

Authors:  K Boucher; A Zorin; A Y Yakovlev; M Mayer-Proschel; M Noble
Journal:  J Math Biol       Date:  2001-07       Impact factor: 2.259

3.  Evidence for migration of oligodendrocyte--type-2 astrocyte progenitor cells into the developing rat optic nerve.

Authors:  R K Small; P Riddle; M Noble
Journal:  Nature       Date:  1987 Jul 9-15       Impact factor: 49.962

4.  Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein.

Authors:  Y M Tokumoto; D G Tang; M C Raff
Journal:  EMBO J       Date:  2001-09-17       Impact factor: 11.598

5.  Posttranscriptional regulation of p18 and p27 Cdk inhibitor proteins and the timing of oligodendrocyte differentiation.

Authors:  Yasuhito M Tokumoto; James A Apperly; Fen-Biao Gao; Martin C Raff
Journal:  Dev Biol       Date:  2002-05-01       Impact factor: 3.582

6.  Oligodendrocyte precursor cells from different brain regions express divergent properties consistent with the differing time courses of myelination in these regions.

Authors:  Jennifer Power; Margot Mayer-Pröschel; Joel Smith; Mark Noble
Journal:  Dev Biol       Date:  2002-05-15       Impact factor: 3.582

7.  An age-dependent branching process model for the analysis of CFSE-labeling experiments.

Authors:  Ollivier Hyrien; Rui Chen; Martin S Zand
Journal:  Biol Direct       Date:  2010-06-22       Impact factor: 4.540

8.  Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.

Authors:  F Ali-Osman; J Giblin; D Dougherty; M L Rosenblum
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

9.  Pharmacokinetics of BCNU in man: a preliminary study of 20 patients.

Authors:  V A Levin; W Hoffman; R J Weinkam
Journal:  Cancer Treat Rep       Date:  1978-09

10.  Pharmacokinetics and immediate effects of high-dose carmustine in man.

Authors:  W D Henner; W P Peters; J P Eder; K Antman; L Schnipper; E Frei
Journal:  Cancer Treat Rep       Date:  1986-07
View more
  12 in total

1.  Asymptotic behavior of cell populations described by two-type reducible age-dependent branching processes with non-homogeneous immigration().

Authors:  Ollivier Hyrien; Nikolay M Yanev
Journal:  Math Popul Stud       Date:  2012-10-05       Impact factor: 0.720

Review 2.  Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment.

Authors:  Erin M Gibson; Michelle Monje
Journal:  Curr Opin Oncol       Date:  2019-11       Impact factor: 3.645

Review 3.  Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis.

Authors:  Michelle Monje; Jörg Dietrich
Journal:  Behav Brain Res       Date:  2011-05-23       Impact factor: 3.332

4.  Quasi- and pseudo-maximum likelihood estimators for discretely observed continuous-time Markov branching processes.

Authors:  Rui Chen; Ollivier Hyrien
Journal:  J Stat Plan Inference       Date:  2011-07-01       Impact factor: 1.111

5.  Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment.

Authors:  Erin M Gibson; Surya Nagaraja; Alfonso Ocampo; Lydia T Tam; Lauren S Wood; Praveen N Pallegar; Jacob J Greene; Anna C Geraghty; Andrea K Goldstein; Lijun Ni; Pamelyn J Woo; Ben A Barres; Shane Liddelow; Hannes Vogel; Michelle Monje
Journal:  Cell       Date:  2018-12-06       Impact factor: 41.582

6.  Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors.

Authors:  Shelli Kesler; Michelle Janelsins; Della Koovakkattu; Oxana Palesh; Karen Mustian; Gary Morrow; Firdaus S Dhabhar
Journal:  Brain Behav Immun       Date:  2012-06-12       Impact factor: 7.217

7.  Cognitive and brain structural changes in long-term oligodendroglial tumor survivors.

Authors:  Nuria Cayuela; Esteban Jaramillo-Jiménez; Estela Càmara; Carles Majós; Noemi Vidal; Anna Lucas; Miguel Gil-Gil; Francesc Graus; Jordi Bruna; Marta Simó
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

8.  White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.

Authors:  Fayez Estephan; Xiaobu Ye; Omar Dzaye; Nina Wagner-Johnston; Lode Swinnen; Douglas E Gladstone; Rich Ambinder; David Olayinka Kamson; Sebastian Lambrecht; Stuart A Grossman; Doris D M Lin; Matthias Holdhoff
Journal:  J Neurooncol       Date:  2019-10-16       Impact factor: 4.130

9.  Higher cardiorespiratory fitness levels are associated with greater hippocampal volume in breast cancer survivors.

Authors:  Laura Chaddock-Heyman; Michael J Mackenzie; Krystle Zuniga; Gillian E Cooke; Elizabeth Awick; Sarah Roberts; Kirk I Erickson; Edward McAuley; Arthur F Kramer
Journal:  Front Hum Neurosci       Date:  2015-08-26       Impact factor: 3.169

10.  Systemic chemotherapy decreases brain glucose metabolism.

Authors:  Laura L Horky; Victor H Gerbaudo; Alexander Zaitsev; Wen Plesniak; Jon Hainer; Usha Govindarajulu; Ron Kikinis; Jörg Dietrich
Journal:  Ann Clin Transl Neurol       Date:  2014-10-01       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.